Overview

• The FTC opened a 60-day public inquiry on July 28 to assess whether providers violated Sections 5 and 12 of the FTC Act by making false claims or omitting material risks in gender-affirming care for minors.
• The inquiry follows a July 9 workshop that featured academics, detransitioners, parents and medical professionals sharing testimonies about potential consumer harms.
• The Department of Justice has issued nearly 20 subpoenas to clinics and drugmakers under investigations into health care fraud, false statements and related violations in youth transition services.
• Major health systems including Kaiser Permanente, D.C. Children’s National Hospital and Stanford Medicine have paused or ended gender-affirming treatments for minors in response to legal and funding pressures.
• Leading medical organizations such as the American Medical Association and American Academy of Pediatrics continue to endorse gender-affirming care as medically necessary, while LGBTQ advocacy groups argue that federal probes threaten access for transgender youth.